New and Legacy Study Optimization Using CDISC Standards With Formedix

Join leading provider of clinical trial automation software, Formedix, on April 24, for a learning webinar looking at how to optimize both new and legacy studies using CDISC standards.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
Standards are there for so much more than regulatory requirements.

Burlington, MA (PRWEB) April 15, 2014

Formedix is to host its next learning webinar focusing on the everyday issues affecting those within the clinical trial industry including Clinical Data Managers, Biostatisticians and Standards Directors. On April 24, Kevin Burges, Technical Business and Standards Director, and Mark Wheeldon, CEO, will look at how to use CDISC standards to optimize both new and legacy studies.

The webinar presentations will include the following topics:

How to use CDISC data acquisition metadata for both new and legacy studies

What is Define-XML? How does it fit within an end-to-end trial? And, how it is useful for new and legacy studies?

How to establish an end-to-end library, what it really consists of and what CDISC standards should be used

The latest standards and upcoming releases from CDISC, looking at Dataset-XML, SHARE and much more.

Kevin Burges has had a core focus on CDISC since 2000 and was one of the founding members of the CDISC XML Technologies Governance team. As a true industry expert, he will also be discussing the most recent standards’ announcements from CDISC and their practical uses in the course of an entire end-to-end clinical trial process. There will also be the opportunity to ask questions of both Formedix specialists after the webinar presentations. Formedix recently exhibited at the CDISC Europe Interchange in Paris where Kevin was invited to present on the subject of Dataset-XML and the possibilities the standard holds for the future of clinical trials. To download Kevin’s presentation slides, visit the Formedix website.

Formedix has been an active supporter of CDISC since its inception and is still one of the longest standing members. Mark Wheeldon, Formedix CEO, says “It is becoming more and more apparent how essential CDISC standards are as part of the end-to-end clinical trial process. Standards are there for so much more than regulatory requirements - by implementing CDISC standards upfront, you not only increase content reuse but clinical trial efficiencies from study set-up right through to submission.”

To join the upcoming learning webinar, on April 24, register here.

For more information on Formedix clinical trial automation software and consultancy services, contact Formedix.


Contact

  • Nicola Rogerson
    Formedix
    +44 1413534010
    Email